The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•16 April 2026•

1 min read

Brookline Capital Cuts Forte Biosciences FY2026 EPS Forecast Amid Share Dilution

Key Facts

1Brookline Capital Markets cut Forte Biosciences' FY2026 EPS estimate from ($2.72) to ($4.44).

2The company conducted a $150 million public stock offering, leading to share dilution.

3The lead product candidate FB-401 is facing advancement challenges.

Brookline Capital Markets has significantly revised its FY2026 earnings per share forecast for Forte Biosciences (FBRX), lowering the estimate from a loss of $2.72 to a deeper loss of $4.44. The downward revision follows a $150 million public stock offering that has resulted in substantial share dilution for existing investors. Analyst K. Raja highlighted that the company's lead product candidate, FB-401, is currently facing significant advancement and development hurdles. While the capital raise provides necessary liquidity, the dilutive nature of the offering combined with clinical challenges weighs heavily on the firm's valuation. Investors remain cautious as the biotech firm navigates these operational setbacks and financial adjustments.